Vol. 45 | No. 2 | July-December 2017Back

Open Access

Ivabradine Versus Beta-blockers in Mitral Stenosis in Sinus Rhythm: An Updated Meta-analysis of Randomized Controlled Trials

Lauro L. Abrahan IV, John Daniel A. Ramos, Ellen L. Cunanan, Marc Denver A. Tiongson, Felix Eduardo R. Punzalan
Dec 2017 DOI 10.69944/pjc.e01ef85ddf

More Info

Lauro L. Abrahan IV, MD; John Daniel A. Ramos, MD; Ellen L. Cunanan, MD; Marc Denver A. Tiongson, MD; Felix Eduardo R. Punzalan, MD

References
  1. Seckeler MD, Hoke TR. The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease. Clin Epidemiol 2011:3 67–84
  2. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5: 685–694.
  3. Mayosi, Bongani. Natural history, screening, and management of rheumatic heart disease. Available at: www.uptodate.com/contents/ natural-history-screening-and-management-of-rheumatic-heart disease. Accessed 19 Dec 2017.
  4. Jara RD, Tumabiene KD. Valvuloplasty for Rheumatic Mitral Stenosis: The Philippine Experience. Philipp Heart Center J 2013;1(1).
  5. Otto CM, Bonow RO. Valvular Heart Disease. In: Mann, DL., DP Zipes, P Libby, RO Bonnow, and E Braunwald. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 10th edition. USA: Saunders, 2015.
  6. Nishimura RA, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(22).
  7. Stoll BC, Aschom TL, Johns JP, Johnson JE, Rubal BJ. Effects of atenolol on rest and exercise hemodynamics in patients with mitral stenosis. Am J Cardiol. 1995; 75:482-484.
  8. Kumar R, Saran RK, Dwivedi SK, Narain VS, Puri VK, Hasan M, Chandra N, Agrawal A, Sinha N, Ahuja RC. Beneficial effects of long-term metoprolol therapy on cardiac haemodynamics in patients with mitral stenosis in sinus rhythm--a randomised clinical trial. Indian Heart J. 1994 Nov-Dec;46(6):297-301.
  9. Monmeneu Menadas JV, Marín Ortuño F, Reyes Gomis F, Jordán Torrent A, García Martínez M, Bodí Peris V, García de Burgos de Rico E. Beta-blockade and exercise capacity in patients with mitral stenosis in sinus rhythm. J Heart Valve Dis. 2002 Mar;11(2):199-203.
  10. Sulit DV, Punzalan FE. Beta-blockers for mitral stenosis. Cochrane Database Syst Rev 2001;(4): Art. No.: CD003337. DOI: 10.1002/14651858.CD003337
  11. Sulfi S, Timmis AD. Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina. Int J Clin Pract. 2006 Feb;60(2):222-8.
  12. Montalescot G, et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J (2013) 34 (38): 2949- 3003.
  13. Yancy CW, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. 2016.
  14. Karl Swedberg, Michel Komajda, Michael Böhm, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376(9744): 875–885.
  15. Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Sep 6;372(9641):807-16. doi: 10.1016/S0140-6736(08)61170-8.
  16. Agrawal V, Kumar N, Lohiya B, Sihag B, Prajapati R, Singh TB, Subramanian G. Metoprolol vs ivabradine in patients with mitral stenosis in sinus rhythm. Int J Cardiol 2016; 221: 562-566.
  17. Saggu DK, Narain VS, Dwivedi SK, Sethi R, Chandra S, Puri A, Saran RK. Effect of Ivabradine on Heart Rate and Duration of Exercise in Patients with Mild-to-Moderate Mitral Stenosis: A Randomized Comparison with Metoprolol. J Cardiovasc Pharmacol 2015;65:552– 554
  18. Parakh N, Chaturvedi S, Kurian S, and Tyagi S. Effect of ivabradine vs atenolol on heart rate and effort tolerance in patients with mild to moderate mitral stenosis and normal sinus rhythm. J Card Fail 2012; 18 (4): 282-288.
  19. Rajesh GN, Sajeer K, Sajeev CG, Bastian C, Vinayakumar D, Muneer K, Haridasan V, Mathew D, George B, and Krishnan MN. A comparative study of ivabradine and atenolol inpatients with moderate mitral stenosis in sinus rhythm. Indian Heart Journal 2016; 68: 311-315.
  20. Adviento JB, Chiong LL, Aherrera JA, Ramos JD. Ivabradine versus BB in mitral stenosis in sinus rhythm: a meta-analysis of randomized controlled trials. Presented at: Philippine College of Physicians; 2014.
  21. Dhanger, MK. Comparative study of ivabradine versus atenolol in symptomatic mitral stenosis patients. Indian Heart Journal Nov 2014; 66: S133.
  22. Feldman, Arthur M. Ivabradine in Cardiovascular Disease: Heart Rate Isn’t Everything. J Cardiovasc Pharmacol. June 2015; 65(6): 549-551.
  23. Ergün G, Doğan V, Ba aran Ö, Biteker M. Metoprolol vs ivabradine in patients with mitral stenosis. Int J Cardiol. 2016 Nov 15;223:108.
  24. Martin RIR, Pogoryelova O, Santibáñez Koref M, et al. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart Published Online First: 20 June 2014. doi: 10.1136/heartjnl-2014-305482
  25. Tanboğa H, Topçu S, Aksakal E, Gulcu O, Aksakal E, Aksu U, Oduncu V, Ulusoy FR, Sevimli S, Kaymaz C. The Risk of Atrial Fibrillation With Ivabradine Treatment: A Meta-analysis With Trial Sequential Analysis of More Than 40000 Patients. Clin Cardiol. 2016 Oct;39(10):615-620. doi: 10.1002/clc.22578.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.